Skip to main content
. 2021 Jun 11;2021:6632249. doi: 10.1155/2021/6632249

Table 2.

Univariate and multivariate analysis for factors associated with PFS.

Progression-free survival
Median, 95% CI p HR (95% CI) p
Gender Female 18.2 (0-43.1)
Male 7.7 (4.9-10.5) 0.067
Age <60 years 10.3 (5.9-14.7)
≥60 years 18.8 (0.4-37.2) 0.415
Tobacco smokers Nonsmoker 27.3 (3.0-51.7)
Smoker 6.2 (3.8-8.6) 0.163
ECOG PS 0-1 10.3 (0-20.9)
2+ 4.6 (N/R) 0.393
Disease stage IIIB N/R (N/R)
IV 6.5 (4.3-8.6) 0.002 1.6 (0.7-4.0) 0.237
Histological subtype Carcinoid NA
Atypical
Large cell
Small cell
Lung metastases Absent 10.3 (0.2-20.4)
Present 3.4 (1.1-5.7) 0.349
Bone metastases Absent 7.8 (1.2-14.4)
Present 10.3 (3.6-17.0) 0.579
Pleural effusion Absent 16.9 (4.1-29.7)
Present 3.4 (0.0-6.8) <0.001 9.4 (2.3-38.5) 0.02
CNS metastases Absent 16.9 (6.8-27.1)
Present 6.5 (4.3-8.6) 0.033 5.2 (1.4-19.3) 0.013
Liver metastases Absent 15.7 (0.0-32.3)
Present 6.0 (0.0-11.9) 0.018 3.1 (1.0-9.6) 0.047
Adrenal metastases Absent 10.3 (3.4-17.2)
Present 7.8 (7.6-8.1) 0.593
CD47 Negative 7.8 (4.9-10.7)
Positive 45.7 (0.0-115.3) 0.059 0.7 (0.2-2.5) 0.620